Emerging applications of anti-angiogenic nanomaterials in oncotherapy

Angiogenesis is the process of generating new blood vessels from pre-existing vasculature. Under normal conditions, this process is delicately controlled by pro-angiogenic and anti-angiogenic factors. Tumor cells can produce plentiful pro-angiogenic molecules promoting pathological angiogenesis for...

Full description

Saved in:
Bibliographic Details
Published in:Journal of controlled release 2023-12, Vol.364, p.61-78
Main Authors: Tang, Bicai, Ma, Wenjuan, Lin, Yunfeng
Format: Article
Language:English
Subjects:
Angiogenesis
Angiogenesis Inhibitors - therapeutic use
Anti-angiogenesis
Anti-tumor therapy
Humans
Nanomaterial
Nanostructures
Nanotechnology
Nanotherapeutics
Neoplasms - pathology
Neovascularization, Pathologic - drug therapy
Neovascularization, Pathologic - pathology
Oncotherapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Angiogenesis is the process of generating new blood vessels from pre-existing vasculature. Under normal conditions, this process is delicately controlled by pro-angiogenic and anti-angiogenic factors. Tumor cells can produce plentiful pro-angiogenic molecules promoting pathological angiogenesis for uncontrollable growth. Therefore, anti-angiogenic therapy, which aims to inhibit tumor angiogenesis, has become an attractive approach for oncotherapy. However, classic anti-angiogenic agents have several limitations in clinical use, such as lack of specific targeting, low bioavailability, and poor therapeutic outcomes. Hence, alternative angiogenic inhibitors are highly desired. With the emergence of nanotechnology, various nanomaterials have been designed for anti-angiogenesis purposes, offering promising features like excellent targeting capabilities, reduced side effects, and enhanced therapeutic efficacy. In this review, we describe tumor vascular features, discuss current dilemma of traditional anti-angiogenic medicines in oncotherapy, and underline the potential of nanomaterials in tumor anti-angiogenic therapy. Moreover, we discuss the current challenges of anti-angiogenic cancer treatment. We expect that this summary of anti-angiogenic nanomaterials in oncotherapy will offer valuable insights, facilitating their extensive applications in the future. Common nanoparticles used in anti-angiogenic therapy for oncotherapy, including metal and metallic oxide NPs, non-metallic NPs, polymeric NPs, liposomes, and others. [Display omitted]
ISSN:0168-3659
1873-4995
DOI:10.1016/j.jconrel.2023.10.022